30
Participants
Start Date
October 21, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Saroglitazar Magnesium 1 mg
Group-8: Total of 18 subjects will be enrolled in the Group-8. Group 8A (n=6, consist of mild hepatic impairment subjects); Group 8B (n=6, consist of moderate hepatic impairment), Group 8C (n=3, consist of severe hepatic impairment and Group 8D (n=3, consist of control subjects with normal hepatic functions).
Saroglitazar Magnesium 2 mg
Group-9: Total of 12 subjects will be enrolled in the Group-9. Group 9A (n=3, consist of mild hepatic impairment subjects); Group 9B (n=3, consist of moderate hepatic impairment), Group 9C (n=3, consist of severe hepatic impairment and Group 9D (n=3, consist of control subjects with normal hepatic functions).
RECRUITING
Zydus US002, Indianapolis
Zydus Therapeutics Inc.
INDUSTRY